Morgan Stanley Upgrades PTC Therapeutics to Equal-Weight, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung upgraded PTC Therapeutics (PTCT) from Underweight to Equal-Weight and increased the price target from $28 to $30.

April 29, 2024 | 9:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PTC Therapeutics was upgraded by Morgan Stanley from Underweight to Equal-Weight with a price target increase from $28 to $30.
The upgrade by Morgan Stanley reflects a more favorable outlook on PTCT, likely due to improved company fundamentals or market conditions. The increase in price target suggests an expectation of higher future stock performance, which could positively influence investor sentiment and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100